News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Amol Akhade: Topline Results From the DESTINY-Breast11 Phase 3 trial were announced by AstraZeneca and Daiichi Sankyo
Amol Akhade/LinkedIn
May 8, 2025, 12:43

Amol Akhade: Topline Results From the DESTINY-Breast11 Phase 3 trial were announced by AstraZeneca and Daiichi Sankyo

Amol Akhade, Senior Consultant Medical Oncologist and Hemato-Oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post on LinkedIn:

“Breaking News in HER2+ Early Breast Cancer.

Today, topline results from the DESTINY-Breast11 Phase 3 trial were announced by AstraZeneca & Daiichi Sankyo:

Neoadjuvant Enhertu (trastuzumab deruxtecan) and THP demonstrated a statistically significant & clinically meaningful improvement in pathological complete response (pCR) compared to standard ddAC and THP in patients with high-risk, locally advanced HER2+ early breast cancer.

  • First Phase 3 trial of Enhertu in early breast cancer.
  • High-risk HER2+ eBC population.
  • Early event-free survival (EFS) trend favoured Enhertu.

This could be a paradigm-shifting moment in the neoadjuvant space!”

Amol Akhade: Topline Results From the DESTINY-Breast11 Phase 3 trial were announced by AstraZeneca and Daiichi Sankyo

More posts featuring Amol Akhade.

Amol Akhade AstraZeneca Breast Cancer cancer Daiichi Sankyo ddAC DESTINY-Breast11 Phase 3 fight against cancer Global fight against cancer HER2 MedOnc Neoadjuvant Enhertu OncoDaily Oncology Pathological complete response pCR Reliance Hospitals Suyog Cancer Clinics THP Trastuzumab deruxtecan
Special Coverage
Blog
May 8, 2025, 13:09
Tinatin Alaverdashvili about ESTRO25 - "Heading back to my country full of motivation and new ideas"
Blog
May 8, 2025, 13:09
ESTRO - Barbara Jereczek-Fossa's Vision for the Society in the Years Ahead
Blog
May 8, 2025, 12:43
Amol Akhade: Topline Results From the DESTINY-Breast11 Phase 3 trial were announced by AstraZeneca and Daiichi Sankyo
Blog
May 8, 2025, 12:36
Luigi Lorini: Virus and Head and Neck Cancer
Blog
May 8, 2025, 11:55
Dr Kaczorowska's insights on the ESO Clinical Training Centres Fellowship Programmes - European School of Oncology
Blog
May 8, 2025, 11:47
The Official Launch of the International Summit in Immuno-Oncology - Santé Arménie Medical Academy
Science
May 8, 2025, 11:36
Yan Leyfman: Gene-Editing Strategies for CAR T Cell Therapies
Blog
May 8, 2025, 11:26
Yvonne Bombard: Genetics Adviser - A Future where Precision Medicine is Deeply Personal and Truly Accessible
Blog
May 8, 2025, 11:16
Sebastian Szmit: The First CardioOncology Meeting in Florence Organized by European Society of Cardiology
Blog
May 8, 2025, 11:08
Mahmoud Hammad: How to Approach a new case of Mediastinal Mass
Blog
May 8, 2025, 10:58
Learn about the fundamentals of GCP and what's new in R3 - AIEOP
Blog
May 8, 2025, 10:53
Miloš Grujić: A big moment for Serbian radiotherapy at ESTRO 25